Hutchison China MediTech Income
What is the Income of Hutchison China MediTech?
The Income of Hutchison China MediTech Ltd. is -$41.98
What is the definition of Income?
Net income available for common shareholders equals net income minus preferred dividends paid.
ttm (trailing twelve months)
Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.
Income of companies in the Health Care sector on LSE compared to Hutchison China MediTech
What does Hutchison China MediTech do?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Companies with income similar to Hutchison China MediTech
- Tuesday Morning has Income of -$42.05
- Cascades has Income of -CAD$42.00
- Calumet has Income of -$42.00
- Altisource Portfolio Solutions S.A has Income of -$42.00
- RM2 International S.A has Income of -$41.99
- RM2 International S.A has Income of -$41.99
- Hutchison China MediTech has Income of -$41.98
- Sihayo Gold has Income of -AUD$41.95
- Kindred Biosciences Inc has Income of -$41.95
- Midland has Income of -HKD$41.92
- Sino Splendid has Income of -HKD$41.89
- Syrah Resources has Income of -$41.84
- SFund International has Income of -HKD$41.84